Evidence map›Paper›PMID 38392897›Full record

ArticlePathogens (Basel, Switzerland)2024

Evaluation of Inactivation Methods for Rift Valley Fever Virus in Mouse Microglia.

Margarita V Rangel, Feliza A Bourguet, Carolyn I Hall, Dina R Weilhammer

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pathogens (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Margarita V RangelBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Feliza A BourguetBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Carolyn I HallEnvironment, Safety & Health, Biosafety & Biogovernance Functional Area, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.
Dina R WeilhammerBiosciences and Biotechnology Division, Lawrence Livermore National Laboratory, Livermore, CA 94550, USA.ORCID 0000-0002-7618-4702
Lawrence Livermore National Laboratory · US

Funding

Lawrence Livermore National Security 17-LW-038U.S. Department of Energy DE-AC52-07NA27344
6 · The paper itself

Abstract

Rift Valley fever phlebovirus (RVFV) is a highly pathogenic mosquito-borne virus with bioweapon potential due to its ability to be spread by aerosol transmission. Neurological symptoms are among the worst outcomes of infection, and understanding of pathogenesis mechanisms within the brain is limited. RVFV is classified as an overlap select agent by the CDC and USDA; therefore, experiments involving fully virulent strains of virus are tightly regulated. Here, we present two methods for inactivation of live virus within samples derived from mouse microglia cells using commercially available kits for the preparation of cells for flow cytometry and RNA extraction. Using the flow cytometry protocol, we demonstrate key differences in the response of primary murine microglia to infection with fully virulent versus attenuated RVFV.

Indexed as

MicrogliaRift Valley FeverRift Valley fever virusVirus InactivationAnimalsCells, CulturedFlow CytometryMicearbovirusesflow cytometryguanidine hydrochlorideinactivationmicroglianeuropathogenesisparaformaldehydeRift Valley fever phlebovirusselect agent

Identifiers

PMID38392897
PMCPMC10892077
OpenAlexW4391752699

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.